B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

Tak 285

0 PubMed studies analyzed

Similar Compounds by Shared Targets

The following compounds share molecular targets with Tak 285, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

ac
4 shared targets
dacomitinib
4 shared targets
canertinib
3 shared targets
varlitinib
3 shared targets
cp
3 shared targets
tribromsalan
3 shared targets
hematoxylin
3 shared targets
zanubrutinib
4 shared targets
iodoquinol
3 shared targets
tirabrutinib
3 shared targets
Loading evidence profile...

This evidence profile for Tak 285 is generated deterministically from 0 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: v20260227-01. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.